Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
Stable Blue-Chip Stocks to Buy Before Earnings Season
Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth. 
Via InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for... 
Via Benzinga
Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-stakes pharmaceutical industry deals. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a 
Via Benzinga
3 Stocks to Sell Immediately Based on the French Election Results
Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts. 
Via InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
7 Safe Haven Stocks to Buy Before the Next Market Correction
Discover resilient safe haven stocks to weather economic fluctuations in restaurants, pharmaceuticals, household products, and retail. 
Via InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... 
Via Benzinga
Exposures Product Safety
Novavax’s Second Act: How a Fallen COVID Star Could Rise from the Ashes
After pulling back following May's "Sanofi surge," don't rule out the potential for further needle-moving news with Novavax stock. 
Via InvestorPlace
Exposures COVID-19
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
There are more marketplace opportunities than just AI which is why these stocks that are outperforming Nvidia have done so well. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant
Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany's healthcare sector. Recent investments by Daiichi Sankyo and Eli Lilly... 
Via Benzinga
Where Will Novavax Be in 1 Year?
We will know a lot more about the vaccine maker's long-term prospects in 12 months. 
Via The Motley Fool
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
Exposures Product Safety
Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. 
Via InvestorPlace
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is It Too Late to Buy Novavax Stock?
Shares of the vaccine maker are trading up 230% this year. 
Via The Motley Fool
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
The integration of AI and healthcare is well underway. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These pharma and biotech players could become long-term winners. 
Via The Motley Fool
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
Exposures COVID-19
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.